Provided by Tiger Trade Technology Pte. Ltd.

Curis

1.09
-0.0200-1.80%
Volume:180.28K
Turnover:196.50K
Market Cap:14.97M
PE:-0.33
High:1.13
Open:1.10
Low:1.05
Close:1.11
52wk High:3.18
52wk Low:0.7710
Shares:13.73M
Float Shares:11.61M
Volume Ratio:0.97
T/O Rate:1.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2814
EPS(LYR):-6.8803
ROE:-2951.24%
ROA:-61.20%
PB:-1.02
PE(LYR):-0.16

Loading ...

Curis files to sell 107.71M shares of common stock for holders

TIPRANKS
·
Feb 14

Curis Inc - to Resale From Time to Time up to 107,706,700 Shares of Common Stock by the Selling Stockholders - SEC Filing

THOMSON REUTERS
·
Feb 14

Curis Inc. gibt Termin für Sonderaktionärstreffen bekannt

Reuters
·
Feb 10

Curis Faces Nasdaq Delisting Risk After Compliance Monitoring Notice

Reuters
·
Feb 10

Curis Targets BTKi-Exposed CLL With New Emavusertib Combo Trial: What Investors Should Watch

TIPRANKS
·
Jan 16

ADVISORY-Alert incorrectly tagged to Curis Inc withdrawn

Reuters
·
Jan 13

Curasight Announces Encouraging Preliminary Data From Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical Utreat in High-Grade Gliomas®

THOMSON REUTERS
·
Jan 13

Curis Announces PIPE Financing and Strategic Capital Strengthening

TIPRANKS
·
Jan 08

Crude Oil Down 2%; ISM Services PMI Surges In December

Benzinga
·
Jan 08

BRIEF-Curis Announces Pricing Of Private Placement Totaling Up To $80.8 Million In Gross Proceeds

Reuters
·
Jan 07

Press Release: Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

Dow Jones
·
Jan 07

ADVISORY-Alert incorrectly tagged to Curis Inc withdrawn

Reuters
·
Dec 19, 2025

Curasight Announces Successful Dosing of First Patient in Phase 1 Trial With Utreat® in Brain Cancer

THOMSON REUTERS
·
Dec 19, 2025

Curis Reports 62.5% Undetectable MRD Rate in Frontline AML Triplet Study

Reuters
·
Dec 09, 2025

Curis Provides Updated Data From Its Frontline Aml Triplet Study

THOMSON REUTERS
·
Dec 09, 2025

Curis Reports Promising Clinical Data for Emavusertib in CNS Lymphoma at SNO Meeting

Reuters
·
Nov 14, 2025

Analysts Offer Insights on Healthcare Companies: Curis (CRIS) and Intensity Therapeutics, Inc. (INTS)

TIPRANKS
·
Nov 13, 2025

Curis’s Strategic Clinical Advancements and Promising Data Drive Buy Rating

TIPRANKS
·
Nov 12, 2025

Curis Inc. Earnings Call: Clinical Progress and Financial Gains

TIPRANKS
·
Nov 09, 2025

Curis Completes Sale of Erivedge Business

TIPRANKS
·
Nov 07, 2025